 CureVac BV NASDAQ:CVAC shares are trading lower by 3.6 at 56 after the CDC said preliminary findings suggest the observed reports of heart inflammation after mRNA COVID-19 vaccines are greater than expected. CureVac a clinical-stage biopharmaceutical company, developing a new class of transformative medicines based on messenger ribonucleic acid that has the potential to improve the lives of people. 